De novo mutations (DNMs) in protein-coding genes are a well-established cause of 42 developmental disorders (DD). However, known DD-associated genes only account for a 43 minority of the observed excess of such DNMs. To identify novel DD-associated genes, we 44 integrated healthcare and research exome sequences on 31,058 DD parent-offspring trios, and 45 developed a simulation-based statistical test to identify gene-specific enrichments of DNMs. We 46 identified 285 significantly DD-associated genes, including 28 not previously robustly associated 47 with DDs. Despite detecting more DD-associated genes than in any previous study, much of the 48 excess of DNMs of protein-coding genes remains unaccounted for. Modelling suggests that 49 over 1,000 novel DD-associated genes await discovery, many of which are likely to be less 50 penetrant than the currently known genes. Research access to clinical diagnostic datasets will 51 be critical for completing the map of dominant DDs. 52 53 enrichment corresponds to an excess of ~15 splice-disrupting synonymous mutations in our 122 cohort, of which six are accounted for by a single recurrent synonymous mutation in KAT6B 123 known to disrupt splicing 21 . 124 125
Introduction 54
It has previously been estimated that ~42-48% of patients with a severe developmental 55 disorder (DD) have a pathogenic de novo mutation (DNM) in a protein coding gene 1, 2 . However, 56 over half of these patients remain undiagnosed despite the identification of hundreds of 57 dominant and X-linked DD-associated genes. This implies that there are more DD relevant 58 genes left to find. Existing methods to detect gene-specific enrichments of damaging DNMs 59 typically ignore much prior information about which variants and genes are more likely to be 60 disease-associated. However, missense variants and protein-truncating variants (PTVs) vary in 61 their impact on protein function [3] [4] [5] [6] . Known dominant DD-associated genes are strongly enriched 62 in the minority of genes that exhibit patterns of strong selective constraint on heterozygous 63
PTVs in the general population 7 . To identify the remaining DD genes, we need to increase our 64 power to detect gene-specific enrichments for damaging DNMs by both increasing sample sizes 65 and improving our statistical methods. In previous studies of pathogenic Copy Number Variation 66 (CNV), utilising healthcare-generated data has been key to achieve much larger sample sizes 67 than would be possible in a research setting alone 8,9 . 68 69 Improved statistical enrichment test identifies 285 significant DD-associated genes 70
Following clear consent practices and only using aggregate, de-identified data, we 71 pooled DNMs in patients with severe developmental disorders from three centres: GeneDx (a 72 US-based diagnostic testing company), the Deciphering Developmental Disorders study, and 73 Radboud University Medical Center. We performed stringent quality control on variants and 74 samples to obtain 45,221 coding and splicing DNMs in 31,058 individuals ( Supplementary Fig.  75 1; Supplementary Table 1 ), which includes data on over 24,000 trios not previously published. 76
These DNMs included 40,992 single nucleotide variants (SNVs) and 4,229 indels. The three 77 cohorts have similar clinical characteristics, male/female ratios, enrichments of DNMs by 78 mutational class, and prevalences of known disorders (Supplementary Fig. 2) . 79
To detect gene-specific enrichments of damaging DNMs, we developed a method 80 named DeNovoWEST (De Novo Weighted Enrichment Simulation Test, 81 https://github.com/queenjobo/DeNovoWEST). DeNovoWEST scores all classes of sequence 82 variants on a unified severity scale based on the empirically-estimated positive predictive value 83 of being pathogenic (Supplementary Fig. 3-4) . We perform two tests per gene: the first is an 84 enrichment test on all nonsynonymous DNMs and the second is a test designed to detect genes 85 likely acting via an altered-function mechanism. This second test combines an enrichment test 86 on missense DNMs with a test of linear clustering of missense DNMs within the gene. We then 87 applied a Bonferroni multiple testing correction accounting for 18,762 x 2 tests, which takes into 88 account the number of genes and two tests per gene. 89
We first applied DeNovoWEST to all individuals in our cohort and identified 281 90 significant genes, 18 more than when using our previous method 1 (Supplementary Fig. 5; Fig.  91 1a). The majority (196/281; 70%) of these significant genes already had sufficient evidence of 92 DD-association to be considered of diagnostic utility (as of late 2019) by all three centres, and 93 we refer to them as "consensus" genes. 54/281 of these significant genes were previously 94 considered diagnostic by one or two centres ("discordant" genes). Applying DeNovoWEST to 95 synonymous DNMs, as a negative control analysis, identified no significantly enriched genes 96 ( Supplementary Fig. 6 ). 97
To discover novel DD-associated genes with greater power, we then applied 98
DeNovoWEST only to DNMs in patients without damaging DNMs in consensus genes (we refer 99 to this subset as 'undiagnosed' patients) and identified 94 significant genes ( Fig. 1b ; 100 Supplementary Fig. 7 ; Supplementary Table 2 ). While 61 of these genes were discordant 101 genes, we identified 33 putative 'novel' DD-associated genes. To further ensure robustness to 102 potential mutation rate variation between genes, we determined whether any of the putative 103 novel DD-associated genes had significantly more synonymous variants in the Genome 104 Aggregation Database 5 (gnomAD) of population variation than expected under our null mutation 105 model (Supplementary Note). We identified 11/33 genes with a significant excess of 106 synonymous variants. For these 11 genes we then repeated the DeNovoWEST test, increasing 107 the null mutation rate by the ratio of observed to expected synonymous variants in gnomAD. 108
Five of these genes then fell below our exome-wide significance threshold and were removed, 109 leaving 28 novel genes, with a median of 10 nonsynonymous DNMs in our dataset ( Fig. 1c ; 110 Supplementary Table 3 ). There were 314 patients with nonsynonymous DNMs in these 28 111 genes (1.0% of our cohort); all DNMs in these genes were inspected in IGV 10 and, of 198 for 112 which experimental validation was attempted, all were confirmed as DNMs in the proband. The 113 DNMs in these novel genes were distributed approximately randomly across the three datasets 114 (no genes with p < 0.001, heterogeneity test). Six of the 28 novel DD-associated genes are 115 further corroborated by OMIM entries or publications, including TFE3 11, 12 for which patients were 116 described in two recent publications. 117
We also investigated whether some synonymous DNMs might be pathogenic by 118 disrupting splicing. We annotated all synonymous DNMs with a splicing pathogenicity score, 119 SpliceAI 20 , and identified a significant enrichment of synonymous DNMs with high SpliceAI 120 scores (≥ 0.8, 1.56-fold enriched, p = 0.0037, Poisson test; Supplementary Table 4 ). This represents the consensus genes, blue represents the discordant genes, and orange represents 141 the novel genes. In (c), green represents the remaining fraction of cases expected to have a 142 pathogenic de novo coding mutation ("remaining") and grey is the fraction of cases that are 143 likely to be explained by other genetic or nongenetic factors ("not de novo"). 144 Taken together, 25.0% of individuals in our combined cohort have a nonsynonymous 145 DNM in one of the consensus or significant DD-associated genes ( Fig. 1d ). We noted 146 significant sex differences in the autosomal burden of nonsynonymous DNMs (Supplementary 147 Fig. 8 ). The rate of nonsynonymous DNMs in consensus autosomal genes was significantly 148 higher in females than males (OR = 1.16, p = 4.4 x 10 -7 , Fisher's exact test; Fig. 1e ), as noted 149 previously 1 . However, the exome-wide burden of autosomal nonsynonymous DNMs in all genes 150 was not significantly different between undiagnosed males and females (OR = 1.03, p = 0.29, 151
Fisher's exact test). This suggests the existence of subtle sex differences in the genetic 152 architecture of DD, especially with regard to known and undiscovered disorders. This could, for 153 example, include sex-biased contribution of polygenic and/or environmental causes of DDs. 154 155
Characteristics of the novel DD-associated genes and disorders 156
Based on semantic similarity 22 
between Human Phenotype Ontology terms, patients with 157
DNMs in the same novel DD-associated gene were less phenotypically similar to each other, on 158 average, than patients with DNMs in a consensus gene (p = 2.3 x 10 -11 , Wilcoxon rank-sum test; 159 Fig. 2a; Supplementary Figure 9 ). This suggests that these novel disorders less often result in 160 distinctive and consistent clinical presentations, which may have made these disorders harder 161 to discover via a phenotype-driven analysis or recognise by clinical presentation alone. Each of 162 these novel disorders requires a detailed genotype-phenotype characterisation, which is beyond 163 the scope of this study. 164
Overall, novel DD-associated genes encode proteins that have very similar functional 165 and evolutionary properties to consensus genes, e.g. developmental expression patterns, 166 network properties and biological functions ( Fig. 2b; Supplementary Table 5 ). Despite the 167 high-level functional similarity between known and novel DD-associated genes, the 168 nonsynonymous DNMs in the more recently discovered DD-associated genes are much more 169 likely to be missense DNMs, and less likely to be PTVs (discordant and novel; p = 1.2 x 10 -25 , 170 chi-squared test). Fifteen of the 28 (54%) of the novel genes only had missense DNMs, and 171 only a minority had more PTVs than missense DNMs. Consequently, we expect that a greater 172 proportion of the novel genes will act via altered-function mechanisms (e.g. dominant negative 173 or gain-of-function). For example, the novel gene PSMC5 (DeNovoWEST p = 2.6 x 10 -15 ) had 174 one inframe deletion and nine missense DNMs, eight of which altered two structurally important 175 amino acids that are both in the AAA+ ATPase domain within the 3D protein structure: properties of consensus and novel DD genes. Properties were chosen as those known to be 186 differential between consensus and non-DD genes. 187
188
We observed that missense DNMs were more likely to affect functional protein domains 189 than other coding regions. We observed a 2.63-fold enrichment (p = 2.2 x 10 -68 , G-test) of 190 missense DNMs residing in protein domains among consensus genes and a 1.80-fold 191 enrichment (p = 8.0 x 10 -5 , G-test) in novel DD-associated genes, but no enrichment for 192 synonymous DNMs ( Supplementary Table 6 ). Four protein domain families in consensus 193 genes were consistently enriched for missense DNMs ( Supplementary Table 7 ): ion transport 194 protein (PF00520, p = 6.9 x 10 -4 , G-test Bonferroni corrected), ligand-gated ion channel 195 (PF00060, p = 4.0 x 10 -6 ), protein kinase domain (PF00069, p = 0.043), and kinesin motor 196 domain (PF00225, p = 0.027). Missense DNMs in all four enriched domain families have 197 previously been associated with DD ( Supplementary Table 8 ) 24-26 . 198 We observed a significant overlap between the 285 DNM-enriched DD-associated genes 199 and a set of 369 previously described cancer driver genes 27 (overlap of 70 genes; p = 1.7 x 10 -200 49 , logistic regression correcting for shet), as observed previously 28, 29 , as well as a significant 201 enrichment of nonsynonymous DNMs in these genes ( Supplementary Table 9 ). This overlap 202 extends to somatic driver mutations: we observe 117 DNMs at 76 recurrent somatic mutations 203 observed in at least three patients in The Cancer Genome Atlas (TCGA) 30 . By modelling the 204 germline mutation rate at these somatic driver mutations, we found that recurrent 205 nonsynonymous mutations in TCGA are enriched 21-fold in the DDD cohort (p < 10 -50 , Poisson 206 test, Supplementary Fig. 11 ), whereas recurrent synonymous mutations in TCGA are not 207 significantly enriched (2.4-fold, p = 0.13, Poisson test). This suggests that this observation is 208 driven by the pleiotropic effects of these mutations in development and tumourigenesis, rather 209 than hypermutability. 210 211
Recurrent mutations and potential new germline selection genes 212
We identified 773 recurrent DNMs (736 SNVs and 37 indels), ranging from 2-36 213 independent observations per DNM, which allowed us to interrogate systematically the factors 214 driving recurrent germline mutation. We considered three potential contributory factors: (i) 215 clinical ascertainment enriching for pathogenic mutations, (ii) greater mutability at specific sites, 216 and (iii) positive selection conferring a proliferative advantage in the male germline, thus 217 increasing the prevalence of sperm containing the mutation 31 . We observed strong evidence 218 that all three factors contribute, but not necessarily mutually exclusively. Clinical ascertainment 219 drives the observation that 65% of recurrent DNMs were in consensus genes, a 5.4-fold 220 enrichment compared to DNMs only observed once (p < 10 -50 , proportion test). Hypermutability 221 underpins the observation that 64% of recurrent de novo SNVs occurred at hypermutable CpG 222 dinucleotides 32 , a 2.0-fold enrichment over DNMs only observed once (p = 3.3 x 10 -68 , chi-223 square test). We also observed a striking enrichment of recurrent mutations at the 224 haploinsufficient DD-associated gene MECP2, in which we observed 11 recurrently mutated 225 SNVs within a 500bp window, nine of which were G to A mutations at a CpG dinucleotide. 226 MECP2 exhibits a highly significant twofold excess of synonymous mutations within gnomAD 5 , 227 suggesting that locus-specific hypermutability might explain this observation. 228
To assess the contribution of germline selection to recurrent DNMs, we initially focused 229 on the 12 known germline selection genes, which all operate through activation of the RAS-230 MAPK signalling pathway 33, 34 . We identified 39 recurrent DNMs in 11 of these genes, 38 of 231 which are missense and all of which are known to be activating in the germline (see 232 Supplement). As expected, given that hypermutability is not the driving factor for recurrent 233 mutation in these germline selection genes, these 39 recurrent DNMs were depleted for CpGs 234 relative to other recurrent mutations (6/39 vs 425/692, p = 3.4 x 10 -8 , chi-squared test). 235
Positive germline selection has been shown to be capable of increasing the apparent 236 mutation rate more strongly 31 than either clinical ascertainment (10-100X in our dataset) or 237 hypermutability (~10X for CpGs). However, only a minority of the most highly recurrent 238 mutations in our dataset are in genes that have been previously associated with germline 239 selection. Nonetheless, several lines of evidence suggested that the majority of these most 240 highly recurrent mutations are likely to confer a germline selective advantage. Based on the 241 recurrent DNMs in known germline selection genes, DNMs under germline selection should be 242 more likely to be activating missense mutations, and should be less enriched for CpG dinucleotides. Table 1 shows the 16 de novo SNVs observed nine or more times in our DNM 244 dataset, only two of which are in known germline selection genes (MAP2K1 and PTPN11). All 245 but two of these 16 de novo SNVs cause missense changes, all but two of these genes cause 246 disease by an altered-function mechanism, and these DNMs were depleted for CpGs relative to 247 all recurrent mutations. Two of the genes with highly recurrent de novo SNVs, SHOC2 and 248 PPP1CB, encode interacting proteins that are known to play a role in regulating the RAS-MAPK 249 pathway, and pathogenic variants in these genes are associated with a Noonan-like 250 syndrome 35 . Moreover, two of these recurrent DNMs are in the same gene SMAD4, which 251 encodes a key component of the TGF-beta signalling pathway, potentially expanding the 252 pathophysiology of germline selection beyond the RAS-MAPK pathway. Confirming germline 253 selection of these mutations will require deep sequencing of testes and/or sperm 34 recurrences in our cohort annotated with relevant information, such as CpG status, whether the 260 impacted gene is a known somatic driver or germline selection gene, and diagnostic gene group 261 (e.g. consensus). "Recur" refers to the number of recurrences. "Likely mechanism" refers to 262 mechanisms attributed to this gene in the published literature. 263
265
Evidence for incomplete penetrance and pre/perinatal death 266 Nonsynonymous DNMs in consensus or significant DD-associated genes accounted for 267 half of the exome-wide nonsynonymous DNM burden associated with DD ( Fig. 1b) . Despite our 268 identification of 285 significantly DD-associated genes, there remains a substantial burden of 269 both missense and protein-truncating DNMs in unassociated genes (those that are neither 270 significant in our analysis nor on the consensus gene list). The remaining burden of protein-271 truncating DNMs is greatest in genes that are intolerant of PTVs in the general population 272 ( Supplementary Fig. 12 ) suggesting that more haploinsufficient (HI) disorders await discovery. 273
We observed that PTV mutability (estimated from a null germline mutation model) was 274 significantly lower in unassociated genes compared to DD-associated genes (p = 4.5 x 10 -68 , 275
Wilcox rank-sum test Fig. 3a) , which leads to reduced statistical power to detect DNM 276 enrichment in unassociated genes. This is consistent with our hypothesis that many more HI 277 disorders await discovery. 278
A key parameter in estimating statistical power to detect novel HI disorders is the fold-279 enrichment of de novo PTVs expected in as yet undiscovered HI disorders. We observed that 280 novel DD-associated HI genes had significantly lower PTV enrichment compared to the 281 consensus HI genes (p = 0.005, Wilcox rank-sum test; Fig. 3b ). Two additional factors that 282 could lower DNM enrichment, and thus power to detect a novel DD-association, are reduced 283 penetrance and increased pre/perinatal death, which here covers spontaneous fetal loss, 284 termination of pregnancy for fetal anomaly, stillbirth, and early neonatal death. To evaluate 285 incomplete penetrance, we investigated whether HI genes with a lower enrichment of protein-286 truncating DNMs in our cohort are associated with greater prevalences of PTVs in the general 287 population. We observed a significant negative correlation (p = 0.031, weighted linear 288 regression) between gene-specific PTV enrichment in our cohort and the gene-specific ratio of 289 PTV to synonymous variants in gnomAD 5 , suggesting that incomplete penetrance does lower de 290 novo PTV enrichment in individual genes in our cohort (Fig. 3c) . 291
Additionally, we observed that the fold-enrichment of protein-truncating DNMs in 292 consensus HI DD-associated genes in our cohort was significantly lower for genes with a 293 medium or high likelihood of presenting with a prenatal structural malformation (p = 4.6 x 10 -5 , 294
Poisson test, Fig. 3d ), suggesting that pre/perinatal death decreases our power to detect some 295 novel DD-associated disorders (see supplement for details). cohort vs the PTV to synonymous ratio found in gnomAD, for genes that are significantly 304 enriched for the number of PTV mutations in our cohort (without any variant weighting). PTV 305 enrichment is shown as log10(enrichment). There is a significant negative relationship (p = 306 0.031, weighted regression). (d) Overall de novo PTV enrichment (observed / expected PTVs) 307 across genes grouped by their clinician-assigned likelihood of presenting with a structural 308 malformation on ultrasound during pregnancy. PTV enrichment is significantly lower for genes 309 with a medium or high likelihood compared to genes with a low likelihood (p = 4.6 x 10 -5 , 310
Poisson test). 311 312
Modelling reveals hundreds of DD genes remain to be discovered 313
To understand the likely trajectory of future DD discovery efforts, we downsampled the 314 current cohort and reran our enrichment analysis (Fig. 4a) . We observed that the number of 315 significant genes has not yet plateaued. Increasing sample sizes should result in the discovery 316 of many novel DD-associated genes. To estimate how many haploinsufficient genes might await 317 discovery, we modelled the likelihood of the observed distribution of protein-truncating DNMs 318 among genes as a function of varying numbers of undiscovered HI DD genes and fold-319 enrichments of protein-truncating DNMs in those genes. We found that the remaining HI burden 320 is most likely spread across ~1000 genes with ~10-fold PTV enrichment (Fig. 4b) . This fold 321 enrichment is three times lower than in known HI DD-associated genes, suggesting that 322 incomplete penetrance and/or pre/perinatal death is much more prevalent among undiscovered 323 HI genes. We modelled the missense DNM burden separately and also observed that the most 324 likely architecture of undiscovered DD-associated genes is one that comprises over 1000 genes 325 with a substantially lower fold-enrichment than in currently known DD-associated genes 326 (Supplemental Fig. 13) . 327
We calculated that a sample size of ~350,000 parent-offspring trios would be needed to 328 have 80% power to detect a 10-fold enrichment of protein-truncating DNMs for a gene with the 329 median PTV mutation rate among currently unassociated genes. Using this inferred 10-fold 330 enrichment among undiscovered HI genes, from our current data we can evaluate the likelihood 331 that any gene in the genome is an undiscovered HI gene, by comparing the likelihood of the 332 number of de novo PTVs observed in each gene to have arisen from the null mutation rate or 333 from a 10-fold increased PTV rate. Among the ~19,000 non-DD-associated genes, ~1,200 were 334 more than three times more likely to have arisen from a 10-fold increased PTV rate, whereas 335 ~7,000 were three times more likely to have no de novo PTV enrichment. 336 In this study, we have discovered 28 novel developmental disorders by developing an 347 improved statistical test for mutation enrichment and applying it to a dataset of exome 348 sequences from 31,058 children with developmental disorders, and their parents. These 28 349 novel genes account for up to 1.0% of our cohort, and inclusion of these genes in diagnostic 350 workflows will catalyse increased diagnosis of similar patients globally. We note that the value of 351 this study for improving diagnostic yield extends well beyond these 28 novel genes; once newly 352 validated discordant genes are included, the total number of genes added to the diagnostic 353 workflows of the three participating centres ranged from 48-65 genes. We have shown that both 354 incomplete penetrance and pre/perinatal death reduce our power to detect novel DDs 355 postnatally, and that one or both of these factors are likely operating considerably more strongly 356 among undiscovered DD-associated genes. In addition, we have identified a set of highly 357 recurrent mutations that are strong candidates for novel germline selection mutations, which 358 would be expected to result in a higher than expected disease incidence that increases 359 dramatically with increased paternal age. 360
Our study represents the largest collection of DNMs for any disease area, and is 361 approximately three times larger than a recent meta-analysis of DNMs from a collection of 362 individuals with autism spectrum disorder, intellectual disability, and/or a developmental 363 disorder 36 . Our analysis included DNMs from 24,348 previously unpublished trios, and we 364 identified ~2.3 times as many significantly DD-associated genes as this previous study when 365 using Bonferroni-corrected exome-wide significance (285 vs 124). In contrast to meta-analyses 366 of published DNMs, the harmonised filtering of candidate DNMs across cohorts in this study 367 should protect against results being confounded by substantial cohort-specific differences in the 368 sensitivity and specificity of detecting DNMs. 369
Here we inferred indirectly that developmental disorders with higher rates of detectable 370 prenatal structural abnormalities had greater pre/perinatal death. The potential size of this effect 371 can be quantified from the recently published PAGE study of genetic diagnoses in a cohort of 372 fetal structural abnormalities 37 . In this latter study, genetic diagnoses were not returned to 373 participants during the pregnancy, and so the genetic diagnostic information itself could not 374 influence pre/perinatal death. In the PAGE study data, 69% of fetal abnormalities with a 375 genetically diagnosable cause died perinatally or neonatally, with termination of pregnancy, fetal 376 demise and neonatal death all contributing. This emphasises the substantial impact that 377 pre/perinatal death can have on reducing the ability to discover novel DDs from postnatal 378 recruitment alone, and motivates the integration of genetic data from prenatal, neonatal and 379 postnatal studies in future analyses. 380
To empower our mutation enrichment testing, we estimated positive predictive values 381 (PPV) of each DNM being pathogenic on the basis of their predicted protein consequence, 382 CADD score 3 , selective constraint against heterozygous PTVs across the gene (shet) 38 , and, for 383 missense variants, presence in a region under selective missense constraint 4 . These PPVs 384 should also be highly informative for variant prioritisation in the diagnosis of dominant 385 developmental disorders. Further work is needed to see whether these PPVs might be 386 informative for recessive developmental disorders, and in other types of dominant disorders. 387
More generally, we hypothesise that empirically-estimated PPVs based on variant enrichment in 388 large datasets will be similarly informative in many other disease areas. 389
We adopted a conservative statistical approach to identifying DD-associated genes. In 390 two previous studies using the same significance threshold, we identified 26 novel DD-391 associated genes 1, 39 However, as the FDR of individual genes depends on the significance of other genes being 395 tested, FDR thresholds are not appropriate for assessing the significance of individual genes, 396 but rather for defining gene-sets. There are 184 consensus genes that did not cross our 397 significance threshold in this study. It is likely that many of these cause disorders that were 398 under-represented in our study due to the ease of clinical diagnosis on the basis of distinctive 399 clinical features or targeted diagnostic testing. These ascertainment biases are, however, not 400 likely to impact the representation of novel DDs in our cohort. 401
Our modelling also suggested that likely over 1,000 DD-associated genes remain to be 402 discovered, and that reduced penetrance and pre/perinatal death will reduce our power to 403 identify these genes through DNM enrichment. Identifying these genes will require both 404 improved analytical methods and greater sample sizes. As sample sizes increase, accurate 405 modelling of gene-specific mutation rates becomes more important. In our analyses of 31,058 406 trios, we observed evidence that mutation rate heterogeneity among genes can lead to over-407 estimating the statistical significance of mutation enrichment based on an exome-wide mutation 408 model. We advocate the development of more granular mutation rate models, based on large-409 scale population variation resources, to ensure that larger studies are robust to mutation rate 410 heterogeneity. 411
We anticipate that the variant-level weights used by DeNovoWEST will improve over 412 time. As reference population samples, such as gnomAD 5 , increase in size, weights based on 413 selective constraint metrics (e.g. shet, regional missense constraint) will improve. Weights could 414 also incorporate more functional information, such as expression in disease-relevant tissues. co-regulation networks can predict whether genes function within a disease-relevant pathway 41 . 418
As a cautionary note, including more functional information may increase power to detect some 419 novel disorders while decreasing power for disorders with pathophysiology different from known 420 disorders. Our analyses also suggest that variant-level weights could be further improved by 421 incorporating other variant prioritisation metrics, such as upweighting variants predicted to 422 impact splicing, variants in particular protein domains, or variants that are somatic driver 423 mutations during tumorigenesis. In developing DeNovoWEST, we initially explored applying 424 both variant-level weights and gene-level weights in separate stages of the analysis, however, 425 subtle but pervasive correlations between gene-level metrics (e.g. shet) and variant-level metrics 426 (e.g. regional missense constraint, CADD) presents statistical challenges to implementation. 427
Finally, the discovery of less penetrant disorders can be empowered by analytical 428 methodologies that integrate both DNMs and rare inherited variants, such as TADA 42 . 429 Nonetheless, using current methods focused on DNMs alone, we estimated that ~350,000 430 parent-child trios would need to be analysed to have ~80% power to detect HI genes with a 10-431 fold PTV enrichment. Discovering non-HI disorders will need even larger sample sizes. 432
Reaching this number of sequenced families will be impossible for an individual research study 433 or clinical centre, therefore it is essential that genetic data generated as part of routine 434 diagnostic practice is shared with the research community such that it can be aggregated to 435 drive discovery of novel disorders and improve diagnostic practice. 436 437 Acknowledgements 438
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